About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer

Novo Nordisk stock price

Two of the year’s biggest investment themes, artificial intelligence and anti-obesity drugs, are finally meeting up, as Novo Nordisk A/S (NYSE: NVO) and Nvidia Corp. (NASDAQ: NVDA) announced a partnership to develop supercomputers.

In tandem with Nvidia’s developers’ conference in March, the Novo Nordisk Foundation said it would build a supercomputer in Denmark using an Nvidia DGX SuperPOD, an AI data center supercomputer. The project will also use other Nvidia gear designed for large-scale AI language modeling.

The Novo Nordisk Foundation has a controlling interest in pharmaceutical giant Novo Nordisk. 

The Export and Investment Fund of Denmark is also an investor in the project, which is designed to help researchers in Denmark collaborate with Nvidia teams to collaborate on pharmaceutical and biotechnology projects, among others. 

AI Computing Power for Healthcare Applications

"Drug discovery, disease diagnosis, and treatment, as well as complicated life science challenges, are examples of areas where extreme AI computing power can enable the positive transformation of our society,” said Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation, in a statement.

The use of artificial intelligence is nothing new in the pharmaceutical industry. 

For example, in 2023, Eli Lilly & Co., (NYSE: LLY), Novo Nordisk’s big rival in the business of making anti-obesity and diabetes treatments, teamed up with pharmaceutical technology specialist XtalPi to identify potential drug candidates. The goal is for Lilly to accelerate the process of clinical trials and commercialization. 

Other big pharmaceuticals that have joined forces with China-based XtalPi include Pfizer Inc. (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ). 

Weight-Loss and Diabetes Drugs Driving Stocks Higher

Novo Nordisk and Lilly are two of the biggest pharmaceutical stocks, by market capitalization. 

Lilly is the largest pharmaceutical in the Health Care Select Sector SPDR Fund (NYSEARCA: XLV). Its recent growth, like Novo Nordisk’s, has been due to the success of anti-obesity and diabetes drugs. 

Because it’s based in Denmark, Novo Nordisk Is not part of the S&P 500, but its value exceeds that of Johnson & Johnson, Merck & Co. Inc. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV), the next three largest S&P pharmaceuticals, after Eli Lilly. 

Upbeat News About Weight-Loss Pill

The race toward better weight-loss drugs has similarities with the race toward faster and better AI processing chips. That’s put not only Nvidia, but also Eli Lilly and Novo Nordisk in the rankings among the world’s most valuable companies.

On March 7, Novo Nordisk stock gapped up almost 9% on upbeat news about clinical trials for weight-loss pill amycretin. You can see that gap on MarketBeat’s Novo Nordisk chart

More Effective Than Injectable Treatment

Early indications show that amycretin may be more effective than Novo Nordisk’s current blockbuster drug, Wegovy, which is injectable. 

Pharmaceutical analysts say if the pill version of the anti-obesity treatment is more effective than Wegovy, it may also be more effective than diabetes drug Ozempic, which contains the same ingredient as Wegovy. 

In addition, what patient wouldn’t favor taking a pill over getting an injection? Even those who aren’t afraid of a shot would welcome the greater convenience of a medication in pill form. 

For its part, Nvidia has been making inroads into the healthcare industry, and not all of them are likely to be well-received.

Nvidia’s Growing Focus on Healthcare

On March 19, also as part of its developers’ conference, Nvidia said it was collaborating with a company called Hippocratic AI on a technology with the hope of building an emotional connection with patients.

Nvidia has also teamed up with AI leader Microsoft Corp. (NASDAQ: MSFT) to advance the use of generative AI in healthcare settings. The partnership is intended to accelerate drug discovery and clinical research, similar to Eli Lilly’s use of AI. 

In addition to the development of pharmaceuticals, the Nvidia and Microsoft healthcare partnership will focus on diagnostic imaging and precision medicine. 

Finally, Nvidia announced a partnership with GE HealthCare Technologies (NASDAQ: GEHC) to develop A technologies for ultrasound applications. 

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.